Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
Autore:
Condra, JH; Petropoulos, CJ; Ziermann, R; Schleif, WA; Shivaprakash, M; Emini, EA;
Indirizzi:
Merck Res Labs, Dept Antiviral Res, W Point, PA 19486 USA Merck Res Labs W Point PA USA 19486 Antiviral Res, W Point, PA 19486 USA ViroLogic, S San Francisco, CA USA ViroLogic S San Francisco CA USAViroLogic, S San Francisco, CA USA
Titolo Testata:
JOURNAL OF INFECTIOUS DISEASES
fascicolo: 3, volume: 182, anno: 2000,
pagine: 758 - 765
SICI:
0022-1899(200009)182:3<758:DRAPVR>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
P-GLYCOPROTEIN; COMBINATION THERAPY; RITONAVIR; SAQUINAVIR; TRANSPORTER; INDINAVIR; SC-52151; FAILURE; BRAIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Condra, JH Merck Res Labs, Dept Antiviral Res, W Point, PA 19486 USA MerckRes Labs W Point PA USA 19486 Res, W Point, PA 19486 USA
Citazione:
J.H. Condra et al., "Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy", J INFEC DIS, 182(3), 2000, pp. 758-765

Abstract

The extent to which human immunodeficiency virus (HIV) type 1 drug resistance compromises therapeutic efficacy is intimately tied to drug potency andexposure. Most HIV-1 protease inhibitors maintain in vivo trough levels above their human serum protein binding-corrected IC95 values for wild-type HIV-1. However, these troughs are well below corrected IC95 values for protease inhibitor-resistant viruses from patients experiencing virologic failure of indinavir and/or nelfinavir. This suggests that none of the single protease inhibitors would be effective after many cases of protease inhibitor failure. However, saquinavir, amprenavir, and indinavir blood levels are increased substantially when each is coadministered with ritonavir, with 12-htroughs exceeding corrected wild-type IC95 by 2-, 7-, and 28-79-fold, respectively. These indinavir and amprenavir troughs exceed IC95 for most protease inhibitor-resistant viruses tested. This suggests that twice-daily indinavir-ritonavir and, to a lesser extent, amprenavir-ritonavir may be effective for many patients with viruses resistant to protease inhibitors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 08:07:43